Indacaterol

• IUPAC: 5-[(R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydrochinolin-2-on

R03AC18

β2 -agonists

Template: Infobox chemical / molecular formula search available

Indacaterol is a drug from the group of β2 -agonists. It is administered via a dry powder inhaler. It expands the bronchi and since November 30, 2009 in the European Union and since 21 October 2010 in Switzerland for the treatment of chronic obstructive pulmonary disease ( COPD) admitted.

Pharmacology

Indacaterol extended as all β2 -agonists by stimulating bronchial β2 -adrenoceptors the bronchi and stimulates Cilientätigkeit. It is characterized by an extremely long casting time of (indacaterol is a so-called uLABA = ultra - long acting beta agonist ). Therefore, it has to be inhaled day in contrast to the long-acting β2 -agonists salmeterol and formoterol only once. Indacaterol shows compared to formoterol an improvement of some lung function parameters. However, it is still unclear whether this is clinically relevant.

Stereoisomerism

Indacaterol is the ( R)-form of 5 - [2 - [(5,6 -diethyl- 2 ,3-dihydro -1H -inden- 2-yl ) amino ]-1 -hydroxyethyl ] -8 - hydroxyquinolin -2 ( 1H)-one, a chiral molecule.

Trade names

Onbrez Breezhaler (A, DE, CH) for the dry powder inhaler